Recent Updates — VXRT

Vaxart reported third-quarter 2026 revenue of $10.6 million, down from $72.4 million in the prior-year period, driven by reduced BARDA contract activity. The company posted a net loss of $17.7 million, or ($0.07) per share, compared to an $8.1 million loss previously. Cash and short-term investments stood at $65.5 million as of September 30, with management anticipating a cash runway into the second quarter of 2027. The firm expects to release topline efficacy data from its Phase 2b COVID-19 trial by mid-year 2027 and announced a new European patent for its norovirus vaccine candidate. Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines administered via tablet.

Vaxart appointed Dr. Raquel C. Bono, a retired U.S. Navy Vice Admiral and board-certified surgeon, to its Board of Directors effective October 16, 2026. The appointment follows a cooperation agreement entered into with a group of stockholders in July 2026. Dr. Bono will serve as Chair of the Stockholder Engagement Committee and on the Nominating and Governance and Clinical and Regulatory Affairs Committees. She brings extensive experience leading healthcare enterprises, including serving as Director of the Defense Health Agency and currently sitting on the board of Humana Inc. Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines.

Vaxart, Inc. reported second quarter 2026 financial results on August 6, 2026. The company generated $27.2 million in revenue, down from $39.7 million in the prior year period, primarily due to lower government contract activity. Research and development expenses decreased to $33.7 million from $49.7 million, while general and administrative expenses rose to $6.6 million from $4.6 million. The company reported a net loss of $13.5 million, or $0.06 per share, compared to a $15.0 million loss in the previous year. Cash, cash equivalents, and investments totaled $64.0 million as of June 30, 2026, providing a runway into the second quarter of 2027. Clinically, Vaxart announced topline safety data from its Phase 2b COVID-19 sentinel cohort of 400 participants, showing no vaccine-related serious adverse events. Topline efficacy and safety data for the full study of approximately 5,000 participants are expected in the first half of 2027. The company operates in the biotechnology industry, developing oral recombinant pill vaccines.